Cardiovascular Pharmacogenomics: Current Status and Future Directions—Report of a National Heart, Lung, and Blood Institute Working Group

Authors

Kiran Musunuru, Brigham and Women's Hospital, Boston and Harvard University
Dan M. Roden, Vanderbilt University
Robin Boineau, National Heart, Lung, and Blood Institute (NHLBI), Bethesda, MD
Michael R. Bristow, University of Colorado
Timothy A. McCaffrey, George Washington UniversityFollow
Christopher Newton-Cheh, Harvard University
Dina N. Paltoo, National Heart, Lung, and Blood Institute (NHLBI), Bethesda, MD
Yves Rosenberg, National Heart, Lung, and Blood Institute (NHLBI), Bethesda, MD
Jay G. Wohlgemuth, Quest Diagnostics Nichols Institute, San Juan Capistrano, CA
Issam Zineh, U.S. Food and Drug Administration, , Silver Spring, MD
Ahmed A.K. Hasan, National Heart, Lung, and Blood Institute (NHLBI), Bethesda, MD

Document Type

Journal Article

Publication Date

4-2012

Journal

Journal of the American Heart Association

Volume

Volume 1, Issue 2

Comments

Journal of the American Heart Association link

Creative Commons License

This work is licensed under a Creative Commons Attribution-Noncommercial 3.0 License

APA Citation

Musunuru, K., Roden, D., Boineau, R., Bristow, M., McCaffrey, T., Newton-Cheh, C., Paltoo, D., & Rosenberg, Y. (2012). Cardiovascular pharmacogenomics: Current status and future directions—report of a national heart, lung, and blood institute working group. Journal of the American Heart Association, 1(2),

Peer Reviewed

1

Open Access

1